Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20785729 | 1.00 | OPRM1 (0.54) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL19261819 | 0.86 | SLC6A4 (0.43) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL20785639 | 0.86 | SLC6A4 (0.43) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL19261820 | 0.80 | SIGMAR1 (0.48) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL20785606 | 0.80 | SLC6A2 (0.55) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL19261776 | 0.80 | SLC6A2 (0.49) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL20457249 | 0.80 | SLC6A2 (0.55) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL3122638 | 0.79 | OPRM1 (0.52) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL3122249 | 0.79 | OPRM1 (0.52) | OPRM1SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL20785716 | 0.78 | SIGMAR1 (0.50) | OPRM1SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | OPRM1 258/4885SLC6A3 92/4885SLC6A2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.